Trials / Completed
CompletedNCT00531063
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
A 2-year Extension to a 1-year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3 mg/Day) of Everolimus With Steroids and Optimized Administration of Cyclosporine in de Novo Renal Transplant Recipients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 237 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2005-08-01
- First posted
- 2007-09-18
- Last updated
- 2011-11-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00531063. Inclusion in this directory is not an endorsement.